Scientists are hopeful about a new mRNA cancer vaccine developed by Merck & Co. and Moderna Inc., which has shown success in preventing melanoma from returning and could usher in a new era of cancer vaccines. This development brings researchers closer to using vaccines to train the immune system to destroy cancer cells.

A new mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. continues to show promise in preventing melanoma recurrence, with a recent breakthrough suggesting it could usher in a new era of cancer vaccines.

Scientists are hopeful about a new mRNA cancer vaccine developed by Merck & Co. and Moderna Inc., which has shown success in preventing melanoma from returning. This development brings researchers closer to using vaccines to train the immune system to destroy cancer cells.

Barron's provides stock grades for Moderna Inc., offering an evaluation of the pharmaceutical company's stock performance and investment outlook.